chloroquine and derivatives - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.01 [0.14, 7.23]< 10%3 studies (3/-)49.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.51 [0.07, 3.68]< 10%1 study (1/-)74.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.34, 1.81]< 10%2 studies (2/-)71.3 %some concernnot evaluable moderateimportant-

safety endpoints 00

adverse events 1.49 [0.40, 5.57]< 185%2 studies (2/-)27.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.